NCT06216470View on ClinicalTrials.gov

Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION]

PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 13, 2024

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
Hepatitis B, Chronic
Interventions
DRUG

VIR-3434

VIR-3434 is a human monoclonal antibody that binds the antigenic loop present in all forms of the surface envelope protein (small, middle, and large HBsAg).

Trial Locations (1)

M5G2C4

RECRUITING

University Health Network, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER